IMAB I-MAB ADS (N Shares)

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025.

Details are as follows:

24th Annual Needham Virtual Healthcare Conference 
Conference Date:April 7-10, 2025
Format:Company Presentation and one-on-one meetings
Presentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ET
Webcast Link:Register
  

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: and follow us on and .

I-Mab Investor & Media Contacts

PJ Kelleher

LifeSci Advisors







EN
26/03/2025

Underlying

IMABI-MAB ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on I-MAB ADS (N Shares)

 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest ...

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong clinical and commercialization expertise in Greater China and other Asian marketsNovaBridge also named Mr. Ian Woo, President and Chief Financial Officer of Everest Medicines, to its Board of Directors, bringing substantial expertise in internationa...

October 29, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NB...

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwideStrategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)Consistent with the new hub-and-spoke business mod...

October 29, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 ...

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg Q2W up to 18 mg/kg Q3WNo differences in efficacy were observed across different CLDN18.2 expression levels, with favorable overall safetyData anchor combination clinical strategy in first line (1L) gastric cancer, a $2B p...

October 22, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Announces Intention to Undertake Strategic Transformation to Glo...

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwideIntention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX)Name change to be effective following shareholde...

October 16, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at ...

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch